News and Events


Biosfered gets FDA approval

The Academic Spin-Off of the University of Turin, Italy, recently received the approval from the Food and Drug Administration (FDA) and it’s now ready to land in the American market

Good news for Biosfered, Cleantech company which commercializes extracts containing highly concentrated bioactive molecules, known for their wide commercial value and biological activity.

The Academic Spin-Off of the University of Turin, Italy, recently received the approval from the Food and Drug Administration (FDA) and it’s thus ready to land in the American market.


Biosfered products are chemically characterized and titrated by using the most advanced mass spectrometry and analytical techniques. The entire range  is based on the guarantee of process quality, focused on high purity levels and low environmental impact.


One of the most innovative products in the range proposed by Biosfered is surely Oximacro®, a cranberry powder and liquid exctract with the highest content of Proanthocyanidins (PACs, 36%) on the market. 

Its quality is assessed by DMAC and HPLC-MS/MS advanced analytical methods.

Its levels of PAC A are >80%, providing a strong protection against UTI.


By the way, Oximacro® will the subject of an interesting seminar which we are organizing and sponsoring at Hi Europe, in Amsterdam, on the opening day of this important fair. The seminar “Oximacro®, a new cranberry extract with 36% PACs tested with the DMAC method” will feature Prof. Massimo E. Maffei – R&D and Sales Director of Biosfered – as speaker.

If you are around in Amstedam and curious to learn more about the seminar, please click HERE for more details.

To discover more about Biosfered range of products, please do not hesitate to contact us; we’ll be glad to help you for any technical and commercial information you need. 

Faravelli Group is actually the official distributor of Biosfered products.

Our email address is faravelli@faravelli.us






Benessere e salute


want to stay up to date on our news?
Sign up to our newsletter!

By subscribing to our newsletter you accept our privacy policy